--- provider: falcon model: Edison Scientific Literature cached: false start_time: '2026-06-13T06:52:45.355970' end_time: '2026-06-13T07:07:53.623180' duration_seconds: 908.27 template_file: templates/gene_research_go_focused.md template_variables: organism: human gene_id: FBXW7 gene_symbol: FBXW7 uniprot_accession: Q969H0 protein_description: 'RecName: Full=F-box/WD repeat-containing protein 7 {ECO:0000305}; AltName: Full=Archipelago homolog {ECO:0000303|PubMed:11565033}; Short=hAgo {ECO:0000303|PubMed:11565033}; AltName: Full=F-box and WD-40 domain-containing protein 7 {ECO:0000305}; AltName: Full=F-box protein FBX30 {ECO:0000305|PubMed:10531037}; AltName: Full=SEL-10 {ECO:0000303|PubMed:12354302}; AltName: Full=hCdc4 {ECO:0000303|PubMed:11565034};' gene_info: Name=FBXW7 {ECO:0000312|HGNC:HGNC:16712}; Synonyms=FBW7 {ECO:0000312|EMBL:AAK57547.1}, FBX30 {ECO:0000312|EMBL:AAK60269.1}, SEL10 {ECO:0000312|EMBL:AAL07271.1}; organism_full: Homo sapiens (Human). protein_family: Not specified in UniProt protein_domains: F-box-like_dom_sf. (IPR036047); F-box_dom. (IPR001810); IFT122/SMU1_beta-prop. (IPR056153); WD40/YVTN_repeat-like_dom_sf. (IPR015943); WD40_PAC1. (IPR020472) provider_config: timeout: null max_retries: 3 parameters: allowed_domains: [] temperature: 0.1 max_embedded_images: 8 citation_count: 42 artifact_count: 1 artifact_sources: edison_answer_artifacts: 1 artifacts: - filename: artifact-00.md path: FBXW7-deep-research-falcon_artifacts/artifact-00.md media_type: text/markdown source: edison_answer_artifacts data_storage_id: null description: Edison artifact artifact-00 --- ## Question # Gene Research for Functional Annotation ## ⚠️ CRITICAL: Gene/Protein Identification Context **BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms. ### Target Gene/Protein Identity (from UniProt): - **UniProt Accession:** Q969H0 - **Protein Description:** RecName: Full=F-box/WD repeat-containing protein 7 {ECO:0000305}; AltName: Full=Archipelago homolog {ECO:0000303|PubMed:11565033}; Short=hAgo {ECO:0000303|PubMed:11565033}; AltName: Full=F-box and WD-40 domain-containing protein 7 {ECO:0000305}; AltName: Full=F-box protein FBX30 {ECO:0000305|PubMed:10531037}; AltName: Full=SEL-10 {ECO:0000303|PubMed:12354302}; AltName: Full=hCdc4 {ECO:0000303|PubMed:11565034}; - **Gene Information:** Name=FBXW7 {ECO:0000312|HGNC:HGNC:16712}; Synonyms=FBW7 {ECO:0000312|EMBL:AAK57547.1}, FBX30 {ECO:0000312|EMBL:AAK60269.1}, SEL10 {ECO:0000312|EMBL:AAL07271.1}; - **Organism (full):** Homo sapiens (Human). - **Protein Family:** Not specified in UniProt - **Key Domains:** F-box-like_dom_sf. (IPR036047); F-box_dom. (IPR001810); IFT122/SMU1_beta-prop. (IPR056153); WD40/YVTN_repeat-like_dom_sf. (IPR015943); WD40_PAC1. (IPR020472) ### MANDATORY VERIFICATION STEPS: 1. **Check if the gene symbol "FBXW7" matches the protein description above** 2. **Verify the organism is correct:** Homo sapiens (Human). 3. **Check if protein family/domains align with what you find in literature** 4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP** ### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature: **DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead: - State clearly: "The gene symbol 'FBXW7' is ambiguous or literature is limited for this specific protein" - Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism") - Describe the protein based ONLY on the UniProt information provided above - Suggest that the protein function can be inferred from domain/family information ### Research Target: Please provide a comprehensive research report on the gene **FBXW7** (gene ID: FBXW7, UniProt: Q969H0) in human. The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims. You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway. We are interested in where in or outside the cell the gene product carries out its function. We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role. Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available. ## Output Question: You are an expert researcher providing comprehensive, well-cited information. Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims. # Gene Research for Functional Annotation ## ⚠️ CRITICAL: Gene/Protein Identification Context **BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms. ### Target Gene/Protein Identity (from UniProt): - **UniProt Accession:** Q969H0 - **Protein Description:** RecName: Full=F-box/WD repeat-containing protein 7 {ECO:0000305}; AltName: Full=Archipelago homolog {ECO:0000303|PubMed:11565033}; Short=hAgo {ECO:0000303|PubMed:11565033}; AltName: Full=F-box and WD-40 domain-containing protein 7 {ECO:0000305}; AltName: Full=F-box protein FBX30 {ECO:0000305|PubMed:10531037}; AltName: Full=SEL-10 {ECO:0000303|PubMed:12354302}; AltName: Full=hCdc4 {ECO:0000303|PubMed:11565034}; - **Gene Information:** Name=FBXW7 {ECO:0000312|HGNC:HGNC:16712}; Synonyms=FBW7 {ECO:0000312|EMBL:AAK57547.1}, FBX30 {ECO:0000312|EMBL:AAK60269.1}, SEL10 {ECO:0000312|EMBL:AAL07271.1}; - **Organism (full):** Homo sapiens (Human). - **Protein Family:** Not specified in UniProt - **Key Domains:** F-box-like_dom_sf. (IPR036047); F-box_dom. (IPR001810); IFT122/SMU1_beta-prop. (IPR056153); WD40/YVTN_repeat-like_dom_sf. (IPR015943); WD40_PAC1. (IPR020472) ### MANDATORY VERIFICATION STEPS: 1. **Check if the gene symbol "FBXW7" matches the protein description above** 2. **Verify the organism is correct:** Homo sapiens (Human). 3. **Check if protein family/domains align with what you find in literature** 4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP** ### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature: **DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead: - State clearly: "The gene symbol 'FBXW7' is ambiguous or literature is limited for this specific protein" - Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism") - Describe the protein based ONLY on the UniProt information provided above - Suggest that the protein function can be inferred from domain/family information ### Research Target: Please provide a comprehensive research report on the gene **FBXW7** (gene ID: FBXW7, UniProt: Q969H0) in human. The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims. You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway. We are interested in where in or outside the cell the gene product carries out its function. We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role. Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available. # Research Report: Human **FBXW7** (UniProt **Q969H0**) — Functional Annotation and Translational Relevance (2023–2024 emphasis) ## Executive summary FBXW7 (also known as **FBW7, hCDC4, SEL10, AGO/archipelago**) is a **substrate-recognition adaptor** of the **SCF (SKP1–CUL1–RBX1) Cullin-RING E3 ubiquitin ligase**, best known for suppressing oncogenic signaling by promoting **polyubiquitination and proteasomal degradation** of phosphorylated client proteins. Its defining biochemical role is **phosphodegron-dependent recognition** (classically the **Cdc4 phosphodegron, CPD**) via a WD40 β-propeller, enabling selective ubiquitin transfer to substrates. Recent 2023–2024 work expands FBXW7’s validated substrate repertoire (e.g., **EGFR**, **LEF1/TCF7L2**, **PINK1**) and clarifies therapy-relevant consequences (anti-EGFR and anti-Wnt resistance mechanisms and vulnerabilities). (cova2023thehighsand pages 1-2, chen2023fbxw7inbreast pages 1-2, boretto2024epidermalgrowthfactor pages 1-2, zhong2024recurrentmutationsin pages 1-2, jeon2024thescffbw7βe3 pages 2-3) ## 1. Target identity verification (critical disambiguation) The target described by UniProt accession **Q969H0** corresponds to **human FBXW7**, an **F-box/WD40 repeat** protein historically named **hCDC4, SEL-10, and AGO/archipelago** in different model organisms and early literature. Multiple peer-reviewed sources explicitly connect these aliases and define the same SCF substrate-receptor function, matching the UniProt domain architecture (F-box + WD40 repeats) and human context. (zhang2020functionandregulation pages 2-3, cova2023thehighsand pages 1-2, fiore2023theroleof pages 1-2) ## 2. Key concepts and definitions (current understanding) ### 2.1 What FBXW7 is (molecular function) FBXW7 is the **substrate receptor** of an **SCF-type E3 ubiquitin ligase**. In SCF complexes, the scaffold **CUL1** and RING protein **RBX1** recruit the E2 enzyme, **SKP1** links the variable F-box adaptor, and **FBXW7 confers substrate specificity** by binding substrates and positioning them for ubiquitination and subsequent proteasomal degradation. (cova2023thehighsand pages 1-2) ### 2.2 Domain architecture FBXW7 proteins share: (i) an N-terminal **dimerization domain**, (ii) an **F-box** (SKP1 binding), and (iii) a C-terminal WD40-repeat **β-propeller** substrate-binding region. This structure directly supports its role as an SCF substrate receptor. (cova2023thehighsand pages 1-2, wang2023fbxw7andhuman pages 1-2) ### 2.3 Isoforms and subcellular localization Human FBXW7 encodes three major N-terminal isoforms with distinct localization: - **FBXW7α**: predominantly **nuclear/nucleoplasmic** (broadly expressed) (zhang2020functionandregulation pages 2-3, cova2023thehighsand pages 1-2) - **FBXW7β**: predominantly **cytoplasmic** (cova2023thehighsand pages 1-2) - **FBXW7γ**: predominantly **nucleolar** (zhang2020functionandregulation pages 2-3, cova2023thehighsand pages 1-2) This compartmentalization is functionally important because it constrains which substrates can be engaged in vivo. (cova2023thehighsand pages 1-2, jeon2024thescffbw7βe3 pages 2-3) ### 2.4 Degrons and phosphodegrons: the CPD concept A **degron** is a sequence feature that confers regulated instability; FBXW7 typically recognizes a **phosphorylated degron** (the **Cdc4 phosphodegron, CPD**) in substrates. A high-affinity CPD described in a 2023 review is **pThr–Pro–Pro–X–pSer**, with the central phosphorylated threonine at the P0 position. The field increasingly recognizes that **low-affinity and noncanonical CPDs** can still be biologically decisive. (cova2023thehighsand pages 1-2, cova2023thehighsand pages 8-10) Kinase signaling creates CPDs; sources explicitly discuss roles for **GSK3** (often as a key CPD-generating kinase) and additional kinases such as **CDK1/2** and **ERK/MAPK** in multi-kinase “priming + phosphorylation” schemes that tune substrate engagement. (cova2023thehighsand pages 8-10, zhang2020functionandregulation pages 4-6, chen2023fbxw7inbreast pages 1-2) ## 3. Core biology: pathways, substrates, and mechanistic evidence ### 3.1 Primary biochemical role in cells FBXW7’s primary function is to **reduce abundance of specific regulatory proteins** by targeting them for **polyubiquitination** and **26S proteasome degradation**, thereby constraining oncogenic transcriptional programs, cell-cycle progression, and survival pathways. (cova2023thehighsand pages 1-2, wang2023fbxw7andhuman pages 1-2) ### 3.2 Canonical substrates (high-confidence) Across multiple 2023 reviews and earlier mechanistic literature, repeatedly supported substrates include: - **Cyclin E** (cell-cycle control) (wang2023fbxw7andhuman pages 1-2, fiore2023theroleof pages 1-2) - **c-MYC** and **c-JUN** (oncogenic transcription factors) (zhang2020functionandregulation pages 4-6, wang2023fbxw7andhuman pages 1-2) - **NOTCH1/NOTCH4** signaling components (zhang2020functionandregulation pages 4-6) - **MCL1** (anti-apoptotic factor; phosphorylation-linked turnover) (zhang2020functionandregulation pages 4-6, wang2023fbxw7andhuman pages 1-2) - **mTOR** pathway components (accumulation noted upon FBXW7 loss) (zhang2020functionandregulation pages 4-6, chen2023fbxw7inbreast pages 1-2) - **BRAF** (noted in 2023 review; and mutation-specific functional impairment discussed in CRC cohort analysis) (cova2023thehighsand pages 1-2, liu2023comprehensivecharacterizationof pages 7-8) Mechanistic specificity often depends on substrate phosphorylation: for example, c-MYC regulation can depend on phosphorylation at **Thr58**, and MCL1 turnover can be triggered by **GSK3-dependent phosphorylation** that initiates ubiquitination and degradation. (zhang2020functionandregulation pages 4-6) ### 3.3 2023–2024 mechanistic expansions and “latest research” highlights #### (A) **EGFR** as an FBXW7 substrate (PNAS 2024) A 2024 primary study identified **EGFR** as a **direct FBXW7 substrate** in human colon organoids, mapping **CPD-like motifs** in the EGFR cytoplasmic tail. Introducing FBXW7 hotspot mutations increased EGFR stability and caused an approximately **10,000-fold reduction in EGF dependency** for organoid growth, functionally linking FBXW7-mediated EGFR turnover to growth-factor addiction. The study also reports reduced sensitivity to EGFR–MAPK inhibitors in FBXW7-mutant organoids and relates this to clinical anti-EGFR response in metastatic CRC. (boretto2024epidermalgrowthfactor pages 1-2) #### (B) Anti-Wnt therapy resistance and lineage plasticity (Science Advances 2024) In RNF43-mutant/RSPO-fusion cancers, FBXW7 mutations were shown to cause **intrinsic resistance to anti-Wnt therapies**. Mechanistically, FBXW7 inactivation stabilizes multiple oncoproteins (including **Cyclin E and MYC**) and leads tumors to lose dependence on **β-catenin signaling**, accompanied by dedifferentiation and loss of lineage specificity. Importantly, these Wnt-independent FBXW7-mutant states were reported to remain susceptible to **multi–cyclin-dependent kinase inhibition**, suggesting an actionable alternative vulnerability. (zhong2024recurrentmutationsin pages 1-2) #### (C) New Wnt-effector substrates **LEF1** and **TCF7L2** (EMBO Mol Med 2023) A 2023 mechanistic endometrial cancer study validated **LEF1** and **TCF7L2** as novel FBXW7-interacting substrates. Co-immunoprecipitation showed interaction that was disrupted by an FBXW7 WD40 “hotspot” substrate-binding mutant, with densitometry ratios decreasing from **1.0 → 0.44** (LEF1) and **1.0 → 0.17** (TCF7L2). This provides direct substrate-binding evidence and supports a mechanistic connection between FBXW7 loss and altered Wnt transcriptional outputs. (brown2023functionalanalysisreveals pages 10-12) #### (D) PINK1 degradation by cytosolic **SCF–FBW7β** (JBC 2024) A 2024 JBC study reports that the cytoplasmic isoform **FBW7β** binds endogenous **PINK1** (interaction detected by co-IP and proximity ligation), primarily in the **cytosol**, and promotes **K48-linked polyubiquitination** and **proteasome-dependent degradation** of PINK1. Mechanistic SCF dependency was supported by cullin-1 perturbation and inhibition of cullin neddylation (MLN4924), which increased PINK1 levels. Functionally, FBW7β depletion increased PINK1 and enhanced CCCP-induced mitophagy, linking FBXW7 to mitochondrial quality control. (jeon2024thescffbw7βe3 pages 1-2, jeon2024thescffbw7βe3 pages 3-6, jeon2024thescffbw7βe3 pages 2-3) ## 4. Quantitative statistics and data points (recent studies) ### 4.1 Colorectal cancer: frequency and survival statistics A 2023 colorectal cancer clinicogenomic analysis reported that FBXW7 mutations occur in approximately **18%** of CRC patients in their dataset, and that FBXW7-mutant CRC cases were associated with higher MSI and TMB and lower chromosomal instability. In that analysis, FBXW7 mutation status overall was associated with **better overall survival** (**HR 0.67**, 95% CI 0.55–0.80; **P < 0.001**). However, the hotspot **R465C** variant was associated with worse outcomes than other FBXW7 mutations, including **R465C vs R465H** (**HR 3.08**, 95% CI 1.28–7.39; **P = 0.0082**). (liu2023comprehensivecharacterizationof pages 7-8) These findings support a key expert-level interpretation: **variant identity matters**—not all FBXW7 alterations are equivalent biologically or clinically. (cova2023thehighsand pages 8-10, liu2023comprehensivecharacterizationof pages 7-8) ### 4.2 Functional effect sizes in primary models - FBXW7 hotspot mutation in colon organoids caused ~**10,000-fold reduced EGF dependence** (a very large phenotypic shift in growth-factor addiction). (boretto2024epidermalgrowthfactor pages 1-2) - WD40 hotspot mutation reduced FBXW7 binding to LEF1 and TCF7L2 to ~**44%** and **17%** of control co-IP signals, respectively. (brown2023functionalanalysisreveals pages 10-12) ## 5. Current applications and real-world implementations ### 5.1 Precision oncology biomarker contexts **Anti-EGFR therapy (metastatic CRC):** The 2024 PNAS organoid and patient-linked study supports the concept that FBXW7 loss can stabilize EGFR via CPD disruption and thereby **negatively modulate response** to anti-EGFR–based regimens and EGFR–MAPK pathway inhibition. This supports practical use of FBXW7 status as a **candidate biomarker** for resistance or faster progression under EGFR-directed therapy, especially in organoid-guided precision approaches. (boretto2024epidermalgrowthfactor pages 1-2) **Anti-Wnt therapy selection:** For RNF43-mutant/RSPO-fusion cancers treated with Wnt-ligand biogenesis inhibitors (e.g., PORCN inhibitors), FBXW7 mutation was proposed as a biomarker of **primary resistance**, motivating alternative strategies (e.g., CDK inhibition). (zhong2024recurrentmutationsin pages 1-2) ### 5.2 Mechanism-informed therapeutic hypotheses (expert synthesis) Contemporary reviews emphasize that FBXW7’s tumor-suppressor role derives from multi-substrate turnover; thus, rather than “inhibiting FBXW7,” translational work often aims to: - target stabilized downstream proteins (e.g., **MCL1** when FBXW7 is impaired), and/or - target pathway consequences of substrate accumulation (EGFR/MAPK; Wnt addiction bypass), and/or - exploit **synthetic vulnerabilities** emerging from rewired cell-cycle control. This strategic framing is consistent with mechanistic evidence for substrate stabilization (Cyclin E/MYC, EGFR) in 2024 primary studies and 2023–2024 reviews emphasizing resistance mechanisms. (wang2023fbxw7andhuman pages 1-2, boretto2024epidermalgrowthfactor pages 1-2, zhong2024recurrentmutationsin pages 1-2) ## 6. Expert opinions and authoritative analysis (from reviews) A 2023 mechanistic review highlights an emerging conceptual refinement: substrate selection is not governed solely by “perfect” CPD matches; **low-affinity substrates and alternative binding modes** can be decisive, and **hotspot WD40 mutations** may differentially disrupt subsets of substrates—helping explain cancer-specific phenotypes and inconsistent clinical associations. (cova2023thehighsand pages 8-10) Cancer-focused reviews in 2023 emphasize FBXW7 as a central SCF adaptor whose loss contributes to malignant progression and therapy resistance through stabilization of multiple proto-oncoproteins and survival factors, reinforcing its role as a **multi-pathway node** rather than a single-pathway regulator. (chen2023fbxw7inbreast pages 1-2, wang2023fbxw7andhuman pages 1-2, fiore2023theroleof pages 1-2) ## 7. Subcellular site of action FBXW7 operates primarily in **intracellular compartments** consistent with its isoform localization: - nuclear substrates (FBXW7α) (cova2023thehighsand pages 1-2) - cytosolic substrates (FBXW7β) including demonstrated cytosolic PINK1 interaction/degradation (jeon2024thescffbw7βe3 pages 1-2, jeon2024thescffbw7βe3 pages 2-3) - nucleolar substrates (FBXW7γ) (cova2023thehighsand pages 1-2) The 2024 PINK1 study provides direct evidence for **cytosolic interaction** between endogenous PINK1 and FBW7β, establishing a concrete locale for one FBXW7-dependent pathway in mitochondrial quality control signaling. (jeon2024thescffbw7βe3 pages 1-2) ## 8. Consolidated evidence map (artifact) The following table provides a compact map of identity, mechanism, substrates, recent studies, and translational implications with publication dates and URLs. | Aspect | Key points | Best recent sources (2023-2024 prioritized) with publication date and URL | |---|---|---| | Identity/complex | FBXW7 in this report matches human UniProt Q969H0 and the historical aliases hCDC4, SEL-10, and AGO/archipelago homolog. It is the substrate-recognition subunit of the SCF (SKP1-CUL1-RBX1-FBXW7) Cullin-RING E3 ubiquitin ligase complex that promotes ubiquitination and proteasomal degradation of phosphorylated substrates, especially growth- and cell-cycle regulators (zhang2020functionandregulation pages 2-3, cova2023thehighsand pages 1-2, fiore2023theroleof pages 1-2). | de la Cova, *Cells* (2023-08), https://doi.org/10.3390/cells12172141; Di Fiore et al., *Cells* (2023-05), https://doi.org/10.3390/cells12101415; Zhang et al., *Oncology Letters* (2020-06), https://doi.org/10.3892/ol.2020.11728 | | Domains/isoforms/localization | FBXW7 contains an N-terminal dimerization region, an F-box that binds SKP1, and a C-terminal WD40 β-propeller substrate-binding domain. Human isoforms are N-terminally distinct: FBXW7α is mainly nuclear/nucleoplasmic, FBXW7β is cytoplasmic, and FBXW7γ is nucleolar; this matches the UniProt F-box/WD40 annotation and explains compartment-specific substrate control (zhang2020functionandregulation pages 2-3, singh2022mapkdependentregulation pages 21-25, cova2023thehighsand pages 1-2, singh2022mapkdependentregulation pages 29-33). | de la Cova, *Cells* (2023-08), https://doi.org/10.3390/cells12172141; Zhang et al., *Oncology Letters* (2020-06), https://doi.org/10.3892/ol.2020.11728 | | Degron recognition/kinases | FBXW7 recognizes phosphorylated Cdc4 phosphodegrons (CPDs) using its WD40 domain; a high-affinity consensus described in recent review is pThr-Pro-Pro-X-pSer, though lower-affinity/noncanonical CPDs also exist. Substrate phosphorylation is often created or reinforced by GSK3, and can involve kinase cascades including CDK1/2 and ERK/MAPK; hotspot arginines such as R465/R479/R505 are critical for phosphodegron recognition and are recurrently mutated in cancer (cova2023thehighsand pages 1-2, cova2023thehighsand pages 8-10, zhang2020functionandregulation pages 4-6, chen2023fbxw7inbreast pages 1-2, singh2022mapkdependentregulation pages 29-33). | de la Cova, *Cells* (2023-08), https://doi.org/10.3390/cells12172141; Chen et al., *J Exp Clin Cancer Res* (2023-09), https://doi.org/10.1186/s13046-023-02767-1 | | Key substrates | Canonical and strongly supported substrates include Cyclin E, c-MYC, c-JUN, NOTCH1/NOTCH4, MCL1, KLF5, mTOR, and BRAF. Recent primary studies extend the substrate list to EGFR (direct target in colorectal organoids/patients), LEF1 and TCF7L2 (endometrial cancer models), and PINK1 via SCF-FBW7β in the cytosol; recent systematic/functional work also highlights context-dependent effects on CRY2, ZEB2, and others (zhang2020functionandregulation pages 4-6, wang2023fbxw7andhuman pages 1-2, boretto2024epidermalgrowthfactor pages 1-2, brown2023functionalanalysisreveals pages 10-12, jeon2024thescffbw7βe3 pages 1-2, jeon2024thescffbw7βe3 pages 3-6). | Boretto et al., *PNAS* (2024-03), https://doi.org/10.1073/pnas.2309902121; Brown et al., *EMBO Mol Med* (2023-08), https://doi.org/10.15252/emmm.202217094; Jeon & Chung, *J Biol Chem* (2024-04), https://doi.org/10.1016/j.jbc.2024.107198 | | 2023-2024 primary study highlights | 2024 PNAS: EGFR was identified as a direct FBXW7 substrate; FBXW7 hotspot-mutant colon organoids showed markedly increased EGFR stability and ~10,000-fold reduced EGF dependence, with poorer response to EGFR-MAPK blockade and faster progression in FBXW7-mutant metastatic CRC on anti-EGFR therapy (boretto2024epidermalgrowthfactor pages 1-2). 2024 Science Advances: FBXW7 mutations in RNF43-mutant/RSPO-fusion cancers caused intrinsic resistance to anti-Wnt therapies, with loss of β-catenin dependence but retained sensitivity to multi-CDK inhibition (zhong2024recurrentmutationsin pages 1-2). 2024 JBC: SCF-FBW7β promoted K48-linked polyubiquitination and proteasomal degradation of PINK1, with endogenous interaction primarily in the cytosol (jeon2024thescffbw7βe3 pages 1-2, jeon2024thescffbw7βe3 pages 3-6, jeon2024thescffbw7βe3 pages 2-3). 2023 EMBO Mol Med: LEF1 and TCF7L2 were validated as novel FBXW7-interacting substrates, and WD40 hotspot mutation weakened binding (LEF1 co-IP ratio ~1.0→0.44; TCF7L2 ~1.0→0.17) (brown2023functionalanalysisreveals pages 10-12). | Boretto et al., *PNAS* (2024-03), https://doi.org/10.1073/pnas.2309902121; Zhong & Virshup, *Science Advances* (2024-04), https://doi.org/10.1126/sciadv.adk1031; Jeon & Chung, *J Biol Chem* (2024-04), https://doi.org/10.1016/j.jbc.2024.107198; Brown et al., *EMBO Mol Med* (2023-08), https://doi.org/10.15252/emmm.202217094 | | Clinical/genomic statistics | FBXW7 is among the most recurrently altered F-box genes in cancer. In CRC, recent summaries place mutation prevalence around 6-10% overall, with cohort-specific estimates near 14.8-18.75% in several Asian series and ~18% in one 2023 clinicogenomic analysis (arrivi2025fbxw7genemutation pages 1-2, liu2023comprehensivecharacterizationof pages 7-8, arrivi2025fbxw7genemutation pages 14-16). In the 2023 Frontiers in Oncology CRC study, patients with FBXW7 mutations had better overall survival overall (HR 0.67, 95% CI 0.55-0.80, P<0.001), but the specific R465C variant had worse survival than other FBXW7 variants (HR 1.6, 95% CI 1.13-3.1, P=0.015) and versus R465H (HR 3.08, 95% CI 1.28-7.39, P=0.0082) (liu2023comprehensivecharacterizationof pages 7-8). RNF43 mutations occur in ~5-10% of pancreatic cancers and RSPO2/3 fusions in ~2-10% of CRC; within that molecular subgroup, FBXW7 mutation marks likely anti-Wnt resistance (zhong2024recurrentmutationsin pages 1-2). | Liu et al., *Frontiers in Oncology* (2023-03), https://doi.org/10.3389/fonc.2023.1154432; Afolabi et al., *Heliyon* (2024-06), https://doi.org/10.1016/j.heliyon.2024.e31471; Zhong & Virshup, *Science Advances* (2024-04), https://doi.org/10.1126/sciadv.adk1031 | | Therapeutic/application implications | Current translational interest centers on biomarker use and pathway-guided therapy rather than direct FBXW7-targeted drugs. FBXW7 status may help predict resistance to anti-EGFR therapy in metastatic CRC, primary resistance to anti-Wnt/PORCN-pathway inhibition in RNF43/RSPO tumors, and altered sensitivity to apoptosis-targeted approaches when MCL1 accumulates. Mechanistically informed alternatives proposed in recent work include multi-CDK inhibition for FBXW7-mutant Wnt-independent tumors, MCL1-directed strategies, and exploiting synthetic vulnerabilities created by FBXW7 loss; reviews also emphasize potential immunotherapy relevance and the need for hotspot-specific interpretation rather than treating all FBXW7 variants as equivalent (arrivi2025fbxw7genemutation pages 19-20, boretto2024epidermalgrowthfactor pages 1-2, arrivi2025fbxw7genemutation pages 20-22, zhong2024recurrentmutationsin pages 1-2). | Wang et al., *Frontiers in Pharmacology* (2024-12), https://doi.org/10.3389/fphar.2024.1505027; Wang et al., *Frontiers in Pharmacology* (2023-11), https://doi.org/10.3389/fphar.2023.1278056; Chen et al., *Frontiers in Oncology* (2023-03), https://doi.org/10.3389/fonc.2023.1147239; Boretto et al., *PNAS* (2024-03), https://doi.org/10.1073/pnas.2309902121 | *Table: This table summarizes verified identity, molecular function, localization, substrates, recent 2023-2024 discoveries, and translational implications for human FBXW7 (UniProt Q969H0). It is useful as a compact evidence map for narrative functional annotation and recent literature synthesis.* ## Limitations of this synthesis - The evidence base retrieved here did not include clinical trial registry records directly; thus, no FBXW7-specific interventional trial IDs are cited. Most “real-world” implementation evidence is observational/biomarker-driven or based on patient-derived organoid studies rather than FBXW7-targeted drugs. (boretto2024epidermalgrowthfactor pages 1-2, zhong2024recurrentmutationsin pages 1-2) ## Key recent references (URLs + publication months) - de la Cova. *The Highs and Lows of FBXW7…* **Cells** (Aug 2023). https://doi.org/10.3390/cells12172141 (cova2023thehighsand pages 1-2) - Chen et al. *FBXW7 in breast cancer…* **J Exp Clin Cancer Res** (Sep 2023). https://doi.org/10.1186/s13046-023-02767-1 (chen2023fbxw7inbreast pages 1-2) - Brown et al. *Functional analysis reveals driver cooperativity…* **EMBO Mol Med** (Aug 2023). https://doi.org/10.15252/emmm.202217094 (brown2023functionalanalysisreveals pages 10-12) - Liu et al. *Comprehensive characterization of FBXW7… CRC* **Frontiers in Oncology** (Mar 2023). https://doi.org/10.3389/fonc.2023.1154432 (liu2023comprehensivecharacterizationof pages 7-8) - Boretto et al. *EGFR is a target of… FBXW7* **PNAS** (Mar 2024). https://doi.org/10.1073/pnas.2309902121 (boretto2024epidermalgrowthfactor pages 1-2) - Zhong & Virshup. *FBXW7 mutations bypass Wnt/β-catenin addiction…* **Science Advances** (Apr 2024). https://doi.org/10.1126/sciadv.adk1031 (zhong2024recurrentmutationsin pages 1-2) - Jeon & Chung. *SCF-FBW7β mediates ubiquitination and degradation of PINK1* **J Biol Chem** (Apr 2024). https://doi.org/10.1016/j.jbc.2024.107198 (jeon2024thescffbw7βe3 pages 1-2) References 1. (cova2023thehighsand pages 1-2): Claire C. de la Cova. The highs and lows of fbxw7: new insights into substrate affinity in disease and development. Cells, 12:2141, Aug 2023. URL: https://doi.org/10.3390/cells12172141, doi:10.3390/cells12172141. This article has 9 citations. 2. (chen2023fbxw7inbreast pages 1-2): Siyu Chen, Ping Leng, Jinlin Guo, and Hao Zhou. Fbxw7 in breast cancer: mechanism of action and therapeutic potential. Journal of Experimental & Clinical Cancer Research : CR, Sep 2023. URL: https://doi.org/10.1186/s13046-023-02767-1, doi:10.1186/s13046-023-02767-1. This article has 42 citations. 3. (boretto2024epidermalgrowthfactor pages 1-2): Matteo Boretto, Maarten H. Geurts, Shashank Gandhi, Ziliang Ma, Nadzeya Staliarova, Martina Celotti, Sangho Lim, Gui-Wei He, Rosemary Millen, Else Driehuis, Harry Begthel, Lidwien Smabers, Jeanine Roodhart, Johan van Es, Wei Wu, and Hans Clevers. Epidermal growth factor receptor (egfr) is a target of the tumor-suppressor e3 ligase fbxw7. Proceedings of the National Academy of Sciences of the United States of America, Mar 2024. URL: https://doi.org/10.1073/pnas.2309902121, doi:10.1073/pnas.2309902121. This article has 29 citations and is from a highest quality peer-reviewed journal. 4. (zhong2024recurrentmutationsin pages 1-2): Zheng Zhong and David M. Virshup. Recurrent mutations in tumor suppressor fbxw7 bypass wnt/β-catenin addiction in cancer. Science Advances, Apr 2024. URL: https://doi.org/10.1126/sciadv.adk1031, doi:10.1126/sciadv.adk1031. This article has 15 citations and is from a highest quality peer-reviewed journal. 5. (jeon2024thescffbw7βe3 pages 2-3): Seo Jeong Jeon and Kwang Chul Chung. The scf-fbw7β e3 ligase mediates ubiquitination and degradation of the serine/threonine protein kinase pink1. Journal of Biological Chemistry, 300:107198, Apr 2024. URL: https://doi.org/10.1016/j.jbc.2024.107198, doi:10.1016/j.jbc.2024.107198. This article has 4 citations and is from a domain leading peer-reviewed journal. 6. (zhang2020functionandregulation pages 2-3): Zheng Zhang, Qiangsheng Hu, Wenyan Xu, Wensheng Liu, Mengqi Liu, Qiqing Sun, Zeng Ye, Guixiong Fan, Yi Qin, Xiaowu Xu, Xianjun Yu, and Shunrong Ji. Function and regulation of f-box/wd repeat-containing protein 7. Oncology Letters, 20:1526-1534, Jun 2020. URL: https://doi.org/10.3892/ol.2020.11728, doi:10.3892/ol.2020.11728. This article has 17 citations and is from a peer-reviewed journal. 7. (fiore2023theroleof pages 1-2): Riccardo Di Fiore, Sherif Suleiman, Rosa Drago-Ferrante, Yashwanth Subbannayya, Sarah Suleiman, Mariela Vasileva-Slaveva, Angel Yordanov, Francesca Pentimalli, Antonio Giordano, and Jean Calleja-Agius. The role of fbxw7 in gynecologic malignancies. May 2023. URL: https://doi.org/10.3390/cells12101415, doi:10.3390/cells12101415. This article has 22 citations. 8. (wang2023fbxw7andhuman pages 1-2): Wanqing Wang, Kaipeng Jiang, Xue Liu, Ju Li, Wenshuo Zhou, Chang Wang, Jiuwei Cui, and Tingting Liang. Fbxw7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies. Frontiers in Pharmacology, Nov 2023. URL: https://doi.org/10.3389/fphar.2023.1278056, doi:10.3389/fphar.2023.1278056. This article has 13 citations. 9. (cova2023thehighsand pages 8-10): Claire C. de la Cova. The highs and lows of fbxw7: new insights into substrate affinity in disease and development. Cells, 12:2141, Aug 2023. URL: https://doi.org/10.3390/cells12172141, doi:10.3390/cells12172141. This article has 9 citations. 10. (zhang2020functionandregulation pages 4-6): Zheng Zhang, Qiangsheng Hu, Wenyan Xu, Wensheng Liu, Mengqi Liu, Qiqing Sun, Zeng Ye, Guixiong Fan, Yi Qin, Xiaowu Xu, Xianjun Yu, and Shunrong Ji. Function and regulation of f-box/wd repeat-containing protein 7. Oncology Letters, 20:1526-1534, Jun 2020. URL: https://doi.org/10.3892/ol.2020.11728, doi:10.3892/ol.2020.11728. This article has 17 citations and is from a peer-reviewed journal. 11. (liu2023comprehensivecharacterizationof pages 7-8): Yiping Liu, Han-Koo Chen, Hua Bao, Jinfeng Zhang, Runda Wu, and Lingjun Zhu. Comprehensive characterization of fbxw7 mutational and clinicopathological profiles in human colorectal cancers. Frontiers in Oncology, Mar 2023. URL: https://doi.org/10.3389/fonc.2023.1154432, doi:10.3389/fonc.2023.1154432. This article has 27 citations. 12. (brown2023functionalanalysisreveals pages 10-12): Matthew Brown, Alicia Leon, Katarzyna Kedzierska, Charlotte Moore, Hayley L Belnoue‐Davis, Susanne Flach, John P Lydon, Francesco J DeMayo, Annabelle Lewis, Tjalling Bosse, Ian Tomlinson, and David N Church. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis. EMBO Molecular Medicine, Aug 2023. URL: https://doi.org/10.15252/emmm.202217094, doi:10.15252/emmm.202217094. This article has 5 citations and is from a highest quality peer-reviewed journal. 13. (jeon2024thescffbw7βe3 pages 1-2): Seo Jeong Jeon and Kwang Chul Chung. The scf-fbw7β e3 ligase mediates ubiquitination and degradation of the serine/threonine protein kinase pink1. Journal of Biological Chemistry, 300:107198, Apr 2024. URL: https://doi.org/10.1016/j.jbc.2024.107198, doi:10.1016/j.jbc.2024.107198. This article has 4 citations and is from a domain leading peer-reviewed journal. 14. (jeon2024thescffbw7βe3 pages 3-6): Seo Jeong Jeon and Kwang Chul Chung. The scf-fbw7β e3 ligase mediates ubiquitination and degradation of the serine/threonine protein kinase pink1. Journal of Biological Chemistry, 300:107198, Apr 2024. URL: https://doi.org/10.1016/j.jbc.2024.107198, doi:10.1016/j.jbc.2024.107198. This article has 4 citations and is from a domain leading peer-reviewed journal. 15. (singh2022mapkdependentregulation pages 21-25): Neha Singh. Mapk dependent regulation of fbxw7 phosphodegrons. ArXiv, 2022. URL: https://doi.org/10.15476/elte.2022.116, doi:10.15476/elte.2022.116. This article has 0 citations. 16. (singh2022mapkdependentregulation pages 29-33): Neha Singh. Mapk dependent regulation of fbxw7 phosphodegrons. ArXiv, 2022. URL: https://doi.org/10.15476/elte.2022.116, doi:10.15476/elte.2022.116. This article has 0 citations. 17. (arrivi2025fbxw7genemutation pages 1-2): Giulia Arrivi, Gabriella Gentile, Michela Roberto, and Donatella Delle Cave. Fbxw7 gene mutation and expression in colorectal cancer (crc): a systematic review from molecular mechanisms to clinical translation. International Journal of Molecular Sciences, 26:11318, Nov 2025. URL: https://doi.org/10.3390/ijms262311318, doi:10.3390/ijms262311318. This article has 1 citations. 18. (arrivi2025fbxw7genemutation pages 14-16): Giulia Arrivi, Gabriella Gentile, Michela Roberto, and Donatella Delle Cave. Fbxw7 gene mutation and expression in colorectal cancer (crc): a systematic review from molecular mechanisms to clinical translation. International Journal of Molecular Sciences, 26:11318, Nov 2025. URL: https://doi.org/10.3390/ijms262311318, doi:10.3390/ijms262311318. This article has 1 citations. 19. (arrivi2025fbxw7genemutation pages 19-20): Giulia Arrivi, Gabriella Gentile, Michela Roberto, and Donatella Delle Cave. Fbxw7 gene mutation and expression in colorectal cancer (crc): a systematic review from molecular mechanisms to clinical translation. International Journal of Molecular Sciences, 26:11318, Nov 2025. URL: https://doi.org/10.3390/ijms262311318, doi:10.3390/ijms262311318. This article has 1 citations. 20. (arrivi2025fbxw7genemutation pages 20-22): Giulia Arrivi, Gabriella Gentile, Michela Roberto, and Donatella Delle Cave. Fbxw7 gene mutation and expression in colorectal cancer (crc): a systematic review from molecular mechanisms to clinical translation. International Journal of Molecular Sciences, 26:11318, Nov 2025. URL: https://doi.org/10.3390/ijms262311318, doi:10.3390/ijms262311318. This article has 1 citations. ## Artifacts - [Edison artifact artifact-00](FBXW7-deep-research-falcon_artifacts/artifact-00.md) ## Citations 1. cova2023thehighsand pages 1-2 2. zhang2020functionandregulation pages 4-6 3. boretto2024epidermalgrowthfactor pages 1-2 4. zhong2024recurrentmutationsin pages 1-2 5. brown2023functionalanalysisreveals pages 10-12 6. liu2023comprehensivecharacterizationof pages 7-8 7. cova2023thehighsand pages 8-10 8. zhang2020functionandregulation pages 2-3 9. fiore2023theroleof pages 1-2 10. singh2022mapkdependentregulation pages 21-25 11. singh2022mapkdependentregulation pages 29-33 12. https://doi.org/10.3390/cells12172141; 13. https://doi.org/10.3390/cells12101415; 14. https://doi.org/10.3892/ol.2020.11728 15. https://doi.org/10.1186/s13046-023-02767-1 16. https://doi.org/10.1073/pnas.2309902121; 17. https://doi.org/10.15252/emmm.202217094; 18. https://doi.org/10.1016/j.jbc.2024.107198 19. https://doi.org/10.1126/sciadv.adk1031; 20. https://doi.org/10.1016/j.jbc.2024.107198; 21. https://doi.org/10.15252/emmm.202217094 22. https://doi.org/10.3389/fonc.2023.1154432; 23. https://doi.org/10.1016/j.heliyon.2024.e31471; 24. https://doi.org/10.1126/sciadv.adk1031 25. https://doi.org/10.3389/fphar.2024.1505027; 26. https://doi.org/10.3389/fphar.2023.1278056; 27. https://doi.org/10.3389/fonc.2023.1147239; 28. https://doi.org/10.1073/pnas.2309902121 29. https://doi.org/10.3390/cells12172141 30. https://doi.org/10.3389/fonc.2023.1154432 31. https://doi.org/10.3390/cells12172141, 32. https://doi.org/10.1186/s13046-023-02767-1, 33. https://doi.org/10.1073/pnas.2309902121, 34. https://doi.org/10.1126/sciadv.adk1031, 35. https://doi.org/10.1016/j.jbc.2024.107198, 36. https://doi.org/10.3892/ol.2020.11728, 37. https://doi.org/10.3390/cells12101415, 38. https://doi.org/10.3389/fphar.2023.1278056, 39. https://doi.org/10.3389/fonc.2023.1154432, 40. https://doi.org/10.15252/emmm.202217094, 41. https://doi.org/10.15476/elte.2022.116, 42. https://doi.org/10.3390/ijms262311318,